Q3 2021 patient services revenues of $316,329 represent a 235% increase over the previous quarter Field Trip continues to advance development of FT-104, a novel psychedelic molecule with pending patents by accelerating activities in manufacturing and preclinical toxicology to acquire the data required for Phase 1 studies. 5 Field Trip Health centers are in operation, with Amsterdam…


Previous articleThe Ultimate Guide to Pets and Psychedelics
Next articleMindMed’s LSD Neutralizer Study Begins